Current treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor

Can daratumumab, bortezomib, and dexamethasone be used in the treatment of relapsed or refractory multiple myeloma with high cytogenetic risk?

Can daratumumab, bortezomib, and dexamethasone be used in the treatment of relapsed or refractory multiple myeloma with high cytogenetic risk?

Posted by on Sep 6, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study assessed the use of daratumumab (Darzalex) plus bortezomib (Velcade)/dexamethasone (Dexasone) or D-Vd versus bortezomib/dexamethasone (Vd) alone as a treatment for patients with high-risk multiple myeloma (MM). The authors found that D-Vd was effective and showed good tolerability...

Read More

Brentuximab vedotin and bendamustine before stem cell transplant in relapsed or refractory classical Hodgkin lymphoma

Brentuximab vedotin and bendamustine before stem cell transplant in relapsed or refractory classical Hodgkin lymphoma

Posted by on Aug 30, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the real-world safety and effectiveness of brentuximab vedotin (BV) and bendamustine before stem cell transplant (SCT) for patients with relapsed or refractory classical Hodgkin lymphoma (cHL).  This study concluded that this treatment is safe and effective as...

Read More

Looking for participants to test a treatment combination for metastatic colorectal cancer

Looking for participants to test a treatment combination for metastatic colorectal cancer

Posted by on Aug 23, 2020 in Colorectal cancer | 0 comments

In a nutshell This phase 2 trial is examining the effectiveness of TAS-102 (Lonsurf) plus oxaliplatin (Eloxatin) in the treatment of metastatic (spread to other parts of the body) colorectal cancer. The main outcome to be measured will be the overall response to the treatment rate. This study is being conducted in New Jersey, US. The details...

Read More

Anlotinib as a third- or further-line therapy for patients with non-small cell lung cancer.

Anlotinib as a third- or further-line therapy for patients with non-small cell lung cancer.

Posted by on Aug 20, 2020 in Lung cancer | 0 comments

In a nutshell This trial was carried out to assess the effectiveness of anlotinib (AL3818) on different subtypes of non-small cell lung cancer (NSCLC). The trial demonstrated that anlotinib improved progression-free survival (PFS) and overall survival (OS) in patients with adenocarcinoma (ACC) and tended to improve survival in...

Read More

The impact of checkpoint blockade therapy in making Hodgkin lymphoma sensitive to future treatment

The impact of checkpoint blockade therapy in making Hodgkin lymphoma sensitive to future treatment

Posted by on Aug 16, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell The study evaluated whether exposure to checkpoint blockade therapy (CBT) can make relapsed/refractory (R/R) Hodgkin lymphoma (HL) sensitive to further treatments. The main finding was that CBT may make patients with R/R-HL responsive to further treatments. Some background While a large percentage of patients with HL can ve cured with...

Read More

The effects of bipolar androgen therapy in men with metastatic castration resistant prostate cancer

The effects of bipolar androgen therapy in men with metastatic castration resistant prostate cancer

Posted by on Jul 19, 2020 in Prostate cancer | 0 comments

In a nutshell The study evaluated outcomes of bipolar androgen therapy (BAT) in men with metastatic castration-resistant prostate cancer (mCRPC) who were continuing drugs targeting androgen receptors (AR). The authors found that BAT was clinically effective in such patients. Some background BAT refers to sequential injections with testosterone in men...

Read More

Cytarabine, aclarubicin and G-CSF as salvage treatment for hard to treat T cell acute lymphoblastic leukemia

Cytarabine, aclarubicin and G-CSF as salvage treatment for hard to treat T cell acute lymphoblastic leukemia

Posted by on Jun 23, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate cytarabine (Cytosar-U), aclarubicin (Aclacin) and G-CSF (Neupogen) as a salvage treatment for adult patients with relapsed or refractory T cell acute lymphoblastic leukemia.   This study concluded that this treatment combination is safe and effective as a salvage treatment...

Read More

Can immunotherapy increase the effectiveness of following treatments for patients with relapsed or unresponsive non-Hodgkin lymphoma?

Can immunotherapy increase the effectiveness of following treatments for patients with relapsed or unresponsive non-Hodgkin lymphoma?

Posted by on Jun 21, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined if pre-treatment with immunotherapy could improve the effectiveness of following treatment for patients with hard-to-treat non-Hodgkin lymphoma (NHL). The results indicated that immunotherapies increased the effectiveness of other treatments such as chemotherapy for some patients. Some background While...

Read More

Zanubrutinib treatment for relapsed or unresponsive small lymphocytic lymphoma

Zanubrutinib treatment for relapsed or unresponsive small lymphocytic lymphoma

Posted by on May 31, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of zanubrutinib in patients with relapsed/unresponsive chronic lymphocytic leukemia and small lymphocytic lymphoma. This study concluded that zanubrutinib was well tolerated and with promising effectiveness in these patients.    Some background Bruton tyrosine...

Read More